Cargando…

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression

PURPOSE: Primary hyperparathyroidism (PHPT) is a common condition affecting people of all ages and is mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use of cinacalcet in PHPT is less clear. METHODS: Searches were conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Cheng Han, Chin, Yip Han, Tan, Marcus Hon Qin, Ng, Jun Xuan, Yang, Samantha Peiling, Kiew, Jolene Jiayu, Khoo, Chin Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424342/
https://www.ncbi.nlm.nih.gov/pubmed/32621588
http://dx.doi.org/10.1530/EC-20-0221
_version_ 1783570319928197120
author Ng, Cheng Han
Chin, Yip Han
Tan, Marcus Hon Qin
Ng, Jun Xuan
Yang, Samantha Peiling
Kiew, Jolene Jiayu
Khoo, Chin Meng
author_facet Ng, Cheng Han
Chin, Yip Han
Tan, Marcus Hon Qin
Ng, Jun Xuan
Yang, Samantha Peiling
Kiew, Jolene Jiayu
Khoo, Chin Meng
author_sort Ng, Cheng Han
collection PubMed
description PURPOSE: Primary hyperparathyroidism (PHPT) is a common condition affecting people of all ages and is mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use of cinacalcet in PHPT is less clear. METHODS: Searches were conducted in Medline and Embase for cinacalcet use in PHPT from induction to 10 April 2020. Articles and conferences abstracts describing the use of cinacalcet for PHPT in prospective or retrospective cohorts and randomized controlled trials restricted to English language only. We initially identified 1301 abstracts. Each article went extraction by two blinded authors on a structured proforma. Continuous outcomes were pooled with weight mean difference (WMD). Quality of included articles was assessed with Newcastle Ottwa Scale and Cochrane Risk of Bias 2.0. RESULTS: Twenty-eight articles were included. Normalization rate of serum Ca levels was reported at 90% (CI: 0.82 to 0.96). Serum levels of Ca and PTH levels were significantly reduced (Ca, WMD: 1.647, CI: −1.922 to −1.371; PTH, WMD: −31.218, CI: −41.671 to −20.765) and phosphate levels significantly increased (WMD: 0.498, CI: 0.400 to 0.596) after cinacalcet therapy. The higher the baseline Ca levels, the greater Ca reduction with cinacalcet treatment. Age and gender did not modify the effect of cinacalcet on serum Ca levels. CONCLUSION: The results from the meta-analysis support the use of cinacalcet as an alternative or bridging therapy to treat hypercalcemia in people with PHPT.
format Online
Article
Text
id pubmed-7424342
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-74243422020-08-17 Cinacalcet and primary hyperparathyroidism: systematic review and meta regression Ng, Cheng Han Chin, Yip Han Tan, Marcus Hon Qin Ng, Jun Xuan Yang, Samantha Peiling Kiew, Jolene Jiayu Khoo, Chin Meng Endocr Connect Research PURPOSE: Primary hyperparathyroidism (PHPT) is a common condition affecting people of all ages and is mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use of cinacalcet in PHPT is less clear. METHODS: Searches were conducted in Medline and Embase for cinacalcet use in PHPT from induction to 10 April 2020. Articles and conferences abstracts describing the use of cinacalcet for PHPT in prospective or retrospective cohorts and randomized controlled trials restricted to English language only. We initially identified 1301 abstracts. Each article went extraction by two blinded authors on a structured proforma. Continuous outcomes were pooled with weight mean difference (WMD). Quality of included articles was assessed with Newcastle Ottwa Scale and Cochrane Risk of Bias 2.0. RESULTS: Twenty-eight articles were included. Normalization rate of serum Ca levels was reported at 90% (CI: 0.82 to 0.96). Serum levels of Ca and PTH levels were significantly reduced (Ca, WMD: 1.647, CI: −1.922 to −1.371; PTH, WMD: −31.218, CI: −41.671 to −20.765) and phosphate levels significantly increased (WMD: 0.498, CI: 0.400 to 0.596) after cinacalcet therapy. The higher the baseline Ca levels, the greater Ca reduction with cinacalcet treatment. Age and gender did not modify the effect of cinacalcet on serum Ca levels. CONCLUSION: The results from the meta-analysis support the use of cinacalcet as an alternative or bridging therapy to treat hypercalcemia in people with PHPT. Bioscientifica Ltd 2020-07-03 /pmc/articles/PMC7424342/ /pubmed/32621588 http://dx.doi.org/10.1530/EC-20-0221 Text en © 2020 The authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Ng, Cheng Han
Chin, Yip Han
Tan, Marcus Hon Qin
Ng, Jun Xuan
Yang, Samantha Peiling
Kiew, Jolene Jiayu
Khoo, Chin Meng
Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title_full Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title_fullStr Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title_full_unstemmed Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title_short Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
title_sort cinacalcet and primary hyperparathyroidism: systematic review and meta regression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424342/
https://www.ncbi.nlm.nih.gov/pubmed/32621588
http://dx.doi.org/10.1530/EC-20-0221
work_keys_str_mv AT ngchenghan cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT chinyiphan cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT tanmarcushonqin cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT ngjunxuan cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT yangsamanthapeiling cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT kiewjolenejiayu cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression
AT khoochinmeng cinacalcetandprimaryhyperparathyroidismsystematicreviewandmetaregression